<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03244514</url>
  </required_header>
  <id_info>
    <org_study_id>07-AnIt-16</org_study_id>
    <nct_id>NCT03244514</nct_id>
  </id_info>
  <brief_title>Biomarker-guided Implementation of the AKI Bundle</brief_title>
  <acronym>PrevAKI-mc</acronym>
  <official_title>Biomarker-guided Implementation of the Cardiovascular (CV) Surgery AKI Bundle to Reduce the Occurrence of AKI After Cardiac Surgery- Prevention of AKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society of Intensive Care Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no specific therapy for acute kidney injury. It is presumed that supportive measures
      improve the care and outcome of patients with acute kidney injury.

      The investigators hypothesize that the implementation of a bundle of supportive measures
      adapted to patients undergoing cardiovascular surgery reduces the occurence of AKI.

      A Randomized prospective multicenter trial is needed to investigate whether the
      implementation of the bundle of measures is effective to prevent AKI in high risk patients
      undergoing cardiac surgery. In this feasibility trial the investigators will analyze the
      compliance rate to the trial protocol in a multicenter, multinational cohort in preparation
      for a large randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance rate</measure>
    <time_frame>48 hours after start of intervention</time_frame>
    <description>proportion of patients who are treated according to the trial protocol: CV surgery AKI bundle fulfilled at all time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of AKI</measure>
    <time_frame>72 hours after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate and severe AKI</measure>
    <time_frame>72 hours after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free-days through of vasoactive medications and mechanical ventilation</measure>
    <time_frame>28 days after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal recovery</measure>
    <time_frame>90 days after start of intervention</time_frame>
    <description>renal recovery is defined as serum creatinine levels &lt; 0.5 mg/dl higher than baseline serum creatinine (creatinine level before surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital stay</measure>
    <time_frame>up to 1 year after start of intervention (until discharge)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with renal replacement therapy</measure>
    <time_frame>90 days after start of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Acute Kidney Injury (Nontraumatic)</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implementation of the cardiovascular surgery AKI bundle
discontinuation of all nephrotoxic agents when possible
optimization of volume status and hemodynamic parameters
close monitoring of serum creatinine, fluid balance and urinary output
avoidance of hyperglycemia
considerations of alternatives to radiocontrast agents
discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period
avoidance of HES, gelatin, and chlorid-rich solutions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients will receive standard of care (according to each center)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>Implementation of the cardiovascular AKI bundle (see arm description)</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)

          -  Urinary [TIMP-2] * [IGFBP7] &gt;= 0.3 4h after CPB

          -  Written informed consent

        Exclusion Criteria:

          -  Preexisting AKI (stage 1 and higher)

          -  Patients with cardiac assist devices (ECMO, LVAD, RVAD, IABP)

          -  Pregnancy, breastfeeding

          -  Known (Glomerulo-)-Nephritis, intersstitial nephritis or vasculitis

          -  CKD with eGFR &lt; 20 mL/min

          -  Dialyses dependent CKD

          -  Prior kidney transplant within the last 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zarbock, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster, Dept. of Anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Zarbock, PhD</last_name>
    <phone>+49-251-83-47252</phone>
    <email>aki@anit.uni-muenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Bergmannsheil Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>D-44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Zahn, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>D-35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinnerk Wulf, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Zarbock, PhD, MD</last_name>
      <email>aki@anit.uni-muenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino Istituto di Ricovero e Cura a Carattere Scientific</name>
      <address>
        <city>Milano</city>
        <zip>I-20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erminio Sisillo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, Zarbock A. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017 Nov;43(11):1551-1561. doi: 10.1007/s00134-016-4670-3. Epub 2017 Jan 21. Erratum in: Intensive Care Med. 2017 Mar 7;:.</citation>
    <PMID>28110412</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>KDIGO-Guideline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

